Pegcetacoplan: Molecular Structure

Molecular Structure#

Pegcetacoplan (APL-2) is a PEGylated cyclic peptide of the compstatin family, representing one of the most advanced examples of peptide drug engineering. Its molecular architecture combines two identical cyclic peptide pharmacophores with a large PEG backbone to achieve the pharmacokinetic profile needed for chronic subcutaneous therapy.

Compstatin Evolution#

The compstatin family originated from phage display screening that identified a 13-amino acid cyclic peptide (ICVVQDWGHHRCT) capable of binding complement C3 and blocking its activation. Pegcetacoplan uses the second-generation analog Cp05, which incorporates a methyltryptophan substitution at position 7 to improve binding affinity and metabolic stability.

Design Principles#

1. Cyclic peptide pharmacophore: The 13-residue cyclic peptide is constrained by a disulfide bond between Cys2 and Cys12, pre-organizing the binding surface for C3 interaction
2. Bivalent architecture: Two identical Cp05 peptide units are conjugated to each end of the PEG linker, potentially enabling bivalent C3 engagement
3. PEGylation: A 40 kDa linear PEG molecule bridges the two peptide units, dramatically reducing renal clearance (the peptide alone would be rapidly filtered) and extending plasma half-life
4. Methyltryptophan: A single unnatural amino acid (N-methyltryptophan at position 7) enhances target affinity compared to the original compstatin

Amino Acid Sequence (Each Peptide Unit)#

Chemical Properties#

Pharmacokinetics#

Subcutaneous (Empaveli, PNH)#

• Half-life: Approximately 8 days
• Dosing: 1,080 mg SC twice weekly achieves sustained C3 inhibition
• Absorption: Subcutaneous absorption from infusion site over 20-30 minutes
• Distribution: The large PEG component limits tissue distribution and maintains plasma levels
• Elimination: Primarily through PEG metabolism; peptide component undergoes proteolysis

Intravitreal (Syfovre, GA)#

• Local delivery: Intravitreal injection achieves high retinal concentrations with minimal systemic exposure
• Ocular half-life: Extended residence in the vitreous cavity
• Systemic exposure: Minimal; no systemic complement suppression at the intravitreal dose
• Dosing frequency: Monthly or every other month maintains therapeutic retinal levels

C3 Binding Mechanism#

Compstatin family peptides bind in a shallow groove in the C-terminal fragment of the C3 beta chain. This binding:

• Sterically blocks access of C3 to C3 convertases, preventing cleavage
• Also binds C3b, preventing its participation in the alternative pathway amplification loop
• Is specific to human and non-human primate C3 (does not bind rodent C3, which limits preclinical animal models)
• Achieves high affinity despite the relatively small peptide size

Structural Comparison#

Stability#

Pegcetacoplan is formulated as a ready-to-use aqueous solution. The PEGylation provides several stability advantages:

• Protection of the peptide component from proteolytic degradation
• Enhanced solubility and formulation stability
• Room temperature stability of Empaveli for up to 14 days (facilitating patient convenience)
• Refrigerated storage at 2-8 degrees C for long-term stability

Related Reading#

• Pegcetacoplan overview and research guide
• Peptides similar to pegcetacoplan
• Pegcetacoplan research evidence
• Zilucoplan molecular structure